CODX Stock Overview
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Co-Diagnostics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.11 |
52 Week High | US$1.89 |
52 Week Low | US$0.97 |
Beta | -0.70 |
1 Month Change | -0.89% |
3 Month Change | -26.00% |
1 Year Change | -23.97% |
3 Year Change | -88.36% |
5 Year Change | -1.77% |
Change since IPO | -80.90% |
Recent News & Updates
Recent updates
One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%
May 18A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)
Apr 14Co-Diagnostics: Hold Thesis Remains Well Intact
Sep 07Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes
Aug 11Co-Diagnostics spikes on shipments of monkeypox test
Jul 11Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)
Jul 06Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant
Jun 21Co-Diagnostics: Where's Eikon?
Apr 03Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate
Mar 28Co-Diagnostics: Swinging For The Fences
Jan 24Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?
Dec 28Why Co-Diagnostics Is A Solid Covid-19 Play
Aug 19Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too
Aug 14Co-Diagnostics gets CE marking for direct saliva SARS-CoV-2 test
Jun 18Co-Diagnostics: No One-Hit Wonder
Jun 04This Just In: Analysts Are Boosting Their Co-Diagnostics, Inc. (NASDAQ:CODX) Outlook for This Year
May 18These Analysts Just Made A Huge Downgrade To Their Co-Diagnostics, Inc. (NASDAQ:CODX) EPS Forecasts
Mar 30US$22.33: That's What Analysts Think Co-Diagnostics, Inc. (NASDAQ:CODX) Is Worth After Its Latest Results
Mar 27Shareholder Returns
CODX | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0.9% | 2.2% | 0.4% |
1Y | -24.0% | 13.3% | 28.8% |
Return vs Industry: CODX underperformed the US Medical Equipment industry which returned 12% over the past year.
Return vs Market: CODX underperformed the US Market which returned 29.5% over the past year.
Price Volatility
CODX volatility | |
---|---|
CODX Average Weekly Movement | 7.7% |
Medical Equipment Industry Average Movement | 7.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CODX's share price has been volatile over the past 3 months.
Volatility Over Time: CODX's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 155 | Dwight Egan | https://www.codiagnostics.com |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings.
Co-Diagnostics, Inc. Fundamentals Summary
CODX fundamental statistics | |
---|---|
Market cap | US$34.70m |
Earnings (TTM) | -US$35.33m |
Revenue (TTM) | US$6.81m |
5.1x
P/S Ratio-1.0x
P/E RatioIs CODX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CODX income statement (TTM) | |
---|---|
Revenue | US$6.81m |
Cost of Revenue | US$4.18m |
Gross Profit | US$2.63m |
Other Expenses | US$37.96m |
Earnings | -US$35.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.13 |
Gross Margin | 38.57% |
Net Profit Margin | -518.68% |
Debt/Equity Ratio | 0% |
How did CODX perform over the long term?
See historical performance and comparison